BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 10232610)

  • 21. Downregulation of Cap43 gene by von Hippel-Lindau tumor suppressor protein in human renal cancer cells.
    Masuda K; Ono M; Okamoto M; Morikawa W; Otsubo M; Migita T; Tsuneyoshi M; Okuda H; Shuin T; Naito S; Kuwano M
    Int J Cancer; 2003 Jul; 105(6):803-10. PubMed ID: 12767066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNFalpha cytotoxicity.
    Caldwell MC; Hough C; Fürer S; Linehan WM; Morin PJ; Gorospe M
    Oncogene; 2002 Jan; 21(6):929-36. PubMed ID: 11840338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells.
    Gorospe M; Egan JM; Zbar B; Lerman M; Geil L; Kuzmin I; Holbrook NJ
    Mol Cell Biol; 1999 Feb; 19(2):1289-300. PubMed ID: 9891063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association.
    Cohen HT; Zhou M; Welsh AM; Zarghamee S; Scholz H; Mukhopadhyay D; Kishida T; Zbar B; Knebelmann B; Sukhatme VP
    Biochem Biophys Res Commun; 1999 Dec; 266(1):43-50. PubMed ID: 10581162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney.
    Yoshida M; Yao M; Ishikawa I; Kishida T; Nagashima Y; Kondo K; Nakaigawa N; Hosaka M
    Genes Chromosomes Cancer; 2002 Dec; 35(4):359-64. PubMed ID: 12378530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Mutation of von Hippel-Lindau gene and expression of vascular endothelial growth factor in sporadic clear cell renal cell carcinoma and their relationships to angiogenesis].
    Zhang N; Gong K; Guo HF; Na X; Wu G; Yang XY; Xin DQ; Na YQ
    Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(19):1620-4. PubMed ID: 15569457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity.
    Blankenship C; Naglich JG; Whaley JM; Seizinger B; Kley N
    Oncogene; 1999 Feb; 18(8):1529-35. PubMed ID: 10102622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
    Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
    Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions.
    Esteban-Barragán MA; Avila P; Alvarez-Tejado M; Gutiérrez MD; García-Pardo A; Sánchez-Madrid F; Landázuri MO
    Cancer Res; 2002 May; 62(10):2929-36. PubMed ID: 12019174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumors.
    Brieger J; Weidt EJ; Schirmacher P; Störkel S; Huber C; Decker HJ
    J Mol Med (Berl); 1999 Jun; 77(6):505-10. PubMed ID: 10475065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor.
    Shang D; Liu Y; Yang P; Chen Y; Tian Y
    Urology; 2012 Apr; 79(4):966.e1-7. PubMed ID: 22341602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein.
    Lee S; Neumann M; Stearman R; Stauber R; Pause A; Pavlakis GN; Klausner RD
    Mol Cell Biol; 1999 Feb; 19(2):1486-97. PubMed ID: 9891082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL.
    Staller P; Sulitkova J; Lisztwan J; Moch H; Oakeley EJ; Krek W
    Nature; 2003 Sep; 425(6955):307-11. PubMed ID: 13679920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma.
    Igarashi H; Esumi M; Ishida H; Okada K
    Cancer; 2002 Jul; 95(1):47-53. PubMed ID: 12115316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis.
    Schoenfeld AR; Parris T; Eisenberger A; Davidowitz EJ; De Leon M; Talasazan F; Devarajan P; Burk RD
    Oncogene; 2000 Nov; 19(51):5851-7. PubMed ID: 11127815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway.
    Qi H; Ohh M
    Cancer Res; 2003 Nov; 63(21):7076-80. PubMed ID: 14612498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer.
    Smith K; Gunaratnam L; Morley M; Franovic A; Mekhail K; Lee S
    Cancer Res; 2005 Jun; 65(12):5221-30. PubMed ID: 15958567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intratumoral heterogeneity of von Hippel-Lindau gene deletions in renal cell carcinoma detected by fluorescence in situ hybridization.
    Moch H; Schraml P; Bubendorf L; Richter J; Gasser TC; Mihatsch MJ; Sauter G
    Cancer Res; 1998 Jun; 58(11):2304-9. PubMed ID: 9622063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.
    Brauch H; Weirich G; Brieger J; Glavac D; Rödl H; Eichinger M; Feurer M; Weidt E; Puranakanitstha C; Neuhaus C; Pomer S; Brenner W; Schirmacher P; Störkel S; Rotter M; Masera A; Gugeler N; Decker HJ
    Cancer Res; 2000 Apr; 60(7):1942-8. PubMed ID: 10766184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumour suppression by the human von Hippel-Lindau gene product.
    Iliopoulos O; Kibel A; Gray S; Kaelin WG
    Nat Med; 1995 Aug; 1(8):822-6. PubMed ID: 7585187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.